Teva Settles Cephalon Case With FTC for $1.2 Billion Over block generic drug competition

Teva Pharmaceutical Industries Ltd. has agreed to pay $1.2 billion in a settlement with the U.S. Federal Trade Commission (FTC), resolving claims that Cephalon Inc. blocked generic drug competition. Teva acquired More...